Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis

Płuciennik,Elżbieta; Nowakowska,Magdalena; Wujcicka,Wioletta I.; Sitkiewicz,Anna; Kazanowska,Bernarda; Zielińska,Elżbieta; Bednarek,Andrzej  K.

doi:10.3892/or.2012.1940

Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis

Authors:
- Elżbieta Płuciennik
- Magdalena Nowakowska
- Wioletta I. Wujcicka
- Anna Sitkiewicz
- Bernarda Kazanowska
- Elżbieta Zielińska
- Andrzej K. Bednarek
View Affiliations

Affiliations: Department of Molecular Cancerogenesis, Medical University of Lodz, 90-752 Lodz, Poland, Department of Pediatric Surgery and Oncology, Medical University of Lodz, 91-738 Lodz, Poland, Department of Bone Marrow Transplantation, Pediatric Oncology, and Hematology, University of Medicine, 50-345 Wroclaw, Poland, Department of Pediatric Oncology and Hematology, Medical University of Lodz, 91-738 Lodz, Poland
Published online on: July 27, 2012 https://doi.org/10.3892/or.2012.1940
Pages: 1417-1422

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Loss of heterozygosity (LOH) in 16q appears in ~20-30% cases of Wilms' tumor. Within this region, known as common fragile site FRA16D, the WWOX tumor suppressor gene is located. Abnormalities of WWOX gene expression levels were observed in many tumor types and were associated with worse prognosis. The purpose of this study was to investigate the role of the WWOX tumor suppressor gene in Wilms' tumor samples. We evaluated the correlation between expression of WWOX and genes involved in proliferation (Ki67), apoptosis (BCL2, BAX), signal transduction (ERBB4, ERBB2, EGFR), cell cycle (CCNE1, CCND1), cell adhesion (CDH1) and transcription (TP73) using real-time RT-PCR in 23 tumor samples. We also analyzed the potential causes of WWOX gene expression reduction i.e., promoter methylation status (MethylScreen method) and loss of heterozygosity (LOH) status. We revealed a positive correlation between WWOX expression and BCL2, BCL2/BAX ratio, EGFR, ERBB4 isoform JM-a, TP73 and negative correlation with both cyclins. Loss of heterozygosity of the WWOX gene was observed only at intron 8, however, it had no influence on the reduction of its expression levels. Contrary to LOH, methylation of the region covering the 3' end of the promoter and part of exon 1 was associated with statistically significant reduction of WWOX gene expression levels. In the present study we reveal that in Wilms' tumors the WWOX expression levels are positively associated with the process of apoptosis, signal transduction through the ErbB4 pathway and EGFR and negatively with the regulation of the cell cycle (by cyclin E1 and D1). Moreover, our analysis indicates that in this type of tumor the expression of the WWOX gene can be regulated by an epigenetic mechanism - its promoter methylation.

View Figures

View References

1	Green DM, D’Angio GJ, Beckwith JB, Breslow NE, Grundy PE, Ritchey ML and Thomas PR: Wilms tumor. CA Cancer J Clin. 461:46–63. 1996. View Article : Google Scholar
2	Li W, Kessler P, Yeger H, Alami J, Reeve AE, Heathcott R, Skeen J and Williams BR: A gene expression signature for relapse of primary wilms tumors. Cancer Res. 65:2592–2601. 2005. View Article : Google Scholar : PubMed/NCBI
3	Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V and Paterson MC: Loss of heterozygosity for chromosomes 16q and 1p in wilms’ tumors predicts an adverse outcome. Cancer Res. 54:2331–2333. 1994.
4	Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology wilms tumor: a report from the national wilms tumor study group. J Clin Oncol. 23:7312–7321. 2005. View Article : Google Scholar
5	Messahel B, Williams R, Ridolfi A, A’hern R, Warren W, Tinworth L, Hobson R, et al: Allele loss at 16q defines poorer prognosis wilms tumour irrespective of treatment approach in the UKW1–3 clinical trials: a children’s cancer and leukaemia group (CCLG) study. Eur J Cancer. 45:819–826. 2009.PubMed/NCBI
6	Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res. 60:2140–2145. 2000.PubMed/NCBI
7	Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI
8	Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, et al: Association of Wwox with ErbB4 in breast cancer. Cancer Res. 67:9330–9336. 2007. View Article : Google Scholar : PubMed/NCBI
9	Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, Trapasso F, et al: Functional association between Wwox tumor suppressor protein and P73, a P53 homolog. Proc Natl Acad Sci USA. 101:4401–4406. 2004. View Article : Google Scholar : PubMed/NCBI
10	Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y and Croce CM: Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res. 64:8256–8261. 2004. View Article : Google Scholar : PubMed/NCBI
11	Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, et al: Fragile histidine triadprotein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer. 115:899–908. 2009. View Article : Google Scholar
12	Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM and Aqeilan RI: Physical association with WWOX suppresses C-Jun transcriptional activity. Cancer Res. 66:11585–11589. 2006. View Article : Google Scholar : PubMed/NCBI
13	Aqeilan RI, Hassan MQ, de Bruin A, Hagan JP, Volinia S, Palumbo T, Hussain S, et al: The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem. 283:21629–21639. 2008. View Article : Google Scholar : PubMed/NCBI
14	Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, Hagan JP, et al: Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA. 104:3949–3954. 2007. View Article : Google Scholar : PubMed/NCBI
15	Maeda N, Semba S, Nakayama S, Yanagihara K and Yokozaki H: Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch. 457:423–432. 2010. View Article : Google Scholar
16	Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapass F, Baffa R, Huebner K, et al: Loss of WWOX expression in gastric carcinoma. Clin Cancer Res. 10:3053–3058. 2004. View Article : Google Scholar : PubMed/NCBI
17	Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M and Croce CM: Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 62:2258–2260. 2002.PubMed/NCBI
18	Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, Rattan S, et al: The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res. 10:2459–2465. 2004. View Article : Google Scholar : PubMed/NCBI
19	Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, et al: WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 63:878–881. 2003.PubMed/NCBI
20	Chen T, Sahin A and Aldaz CM: Deletion map of chromosome 16q inductalcarcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res. 56:5605–5609. 1996.PubMed/NCBI
21	Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, et al: Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 24:1625–1633. 2005. View Article : Google Scholar : PubMed/NCBI
22	Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, Kuroki T, et al: Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res. 1:940–947. 2003.PubMed/NCBI
23	Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I and de Kraker J: Revised international society of paediatric oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol. 38:79–82. 2002. View Article : Google Scholar : PubMed/NCBI
24	Holemon H, Korshunova Y, Ordway JM, Bedell JA, Citek RW, Lakey N, Leon J, et al: MethylScreen: DNA methylation density monitoringusing quantitative PCR. Biotechniques. 43:683–693. 2007. View Article : Google Scholar : PubMed/NCBI
25	Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P and Debiec-Rychter M: 16q heterozygosity loss in Wilms’ tumour in children and its clinical importance. Eur J Surg Oncol. 26:61–66. 2000.
26	Feinberg AP: Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res. 59:S1743–S1746. 1999.PubMed/NCBI
27	Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD and Sukumar S: Cyclin E is a target of WT1 transcriptional repression. J Biol Chem. 277:19627–19632. 2002. View Article : Google Scholar : PubMed/NCBI
28	Berrebi D, Leclerc J, Schleiermacher G, Zaccaria I, Boccon-Gibod L, Fabre M, Jaubert F, et al: High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. PLoS One. 3:e22162008. View Article : Google Scholar : PubMed/NCBI
29	Faussillon M, Monnier L, Junien C and Jeanpierre C: Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms’ tumor. Cancer Lett. 221:67–75. 2005.PubMed/NCBI
30	Scharnhorst V, Dekker P, van der Eb AJ and Jochemsen AG: Physical interaction between wilms tumor 1 and P73 proteins modulates their functions. J Biol Chem. 275:10202–10211. 2000. View Article : Google Scholar : PubMed/NCBI
31	Ghanem MA, van der Kwast TH, Den Hollander JC, Sudaryo MK, van den Heuvel MM, Noordzij MA, Nijman RJ, et al: The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Br J Cancer. 85:1557–1563. 2001. View Article : Google Scholar : PubMed/NCBI
32	Tanaka K, Granata C, Wang Y, O’Briain DS and Puri P: Apoptosis and Bcl-2 oncogene expression in wilms’ tumor. Pediatr Surg Int. 15:243–247. 1999.
33	Wetli SC, Leuschner I, Harms D, Rufle A, Foerster A, Bihl M, Graf N, et al: KIT, PDGFRalpha and EGFR analysis in nephroblastoma. Virchows Arch. 452:637–650. 2008. View Article : Google Scholar : PubMed/NCBI
34	Vasei M, Modjtahedi H, Ale-Booyeh O, Mosallaei A, Kajbafzadeh AM, Shahriari M, Ghaderi AA, et al: Amplification and expression of EGFR and ERBB2 in Wilms’ tumor. Cancer Genet Cytogenet. 194:88–95. 2009.